X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.pharmaceutical-technology.com/news/fda-regeneron-sanofi-polymyalgia-rheumatica/
https://www.globenewswire.com/news-release/2023/03/01/2617778/0/en/Kevzara-sarilumab-Approved-by-FDA-as-First-and-Only-Biologic-Indicated-for-Patients-with-Polymyalgia-Rheumatica.html
https://www.sanofi.com/en/media-room/press-releases/2021/2021-10-12-18-16-27-2312865
https://www.expresspharma.in/msf-demands-newest-covid-19-treatment-recommended-by-who-must-be-accessible-to-all/
https://www.pharmaceutical-technology.com/news/uk-study-arthritis-drugs/
http://www.pharmatimes.com/news/tocilizumab_and_sarilumab_cut_risk_of_death_in_severe_covid-19_patients_1360960
https://www.europeanpharmaceuticalreview.com/news/138660/tocilizumab-and-sarilumab-reduce-covid-19-patient-mortality-by-8-5-percent-data-shows/
http://www.pmlive.com/pharma_news/two_drugs_found_to_reduce_mortality_in_severe_covid-19_patients_1360962
https://www.biospace.com/article/releases/positive-pivotal-data-for-libtayo-cemiplimab-monotherapy-in-locally-advanced-basal-cell-carcinoma-featured-as-a-late-breaking-presentation-at-esmo/?s=73
https://www.fiercepharma.com/pharma/after-latest-kevzara-fail-covid-19-sanofi-and-regeneron-shift-their-attention-elsewhere
https://www.fiercepharma.com/manufacturing/roche-regeneron-join-forces-to-more-than-triple-manufacturing-covid-19-antibody
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sanofi-halts-trials-of-il-6-drug-for-covid-19-india-to-continue-with-trial-of-another-drug-of-similar-class/articleshow/76840599.cms
https://in.reuters.com/article/health-coronavirus-regeneron-pharms/regeneron-sanofi-arthritis-drug-fails-late-stage-study-in-covid-19-patients-idINL4N2E93MD
https://www.marketwatch.com/press-release/sanofi-and-regeneron-provide-update-on-kevzarar-sarilumab-phase-3-us-trial-in-covid-19-patients-2020-07-02?tesla=y
https://www.prnewswire.com/news-releases/regeneron-and-sanofi-provide-update-on-kevzara-sarilumab-phase-3-us-trial-in-covid-19-patients-301087849.html
https://www.bnnbloomberg.ca/arthritis-drug-seen-helping-covid-19-patients-in-small-study-1.1433212
https://www.fiercepharma.com/pharma/regeneron-scales-up-manufacturing-eyes-human-tests-covid-19-antibody-coktail-june
https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/regeneron-sanofi-to-treat-only-critical-covid-19-patients-with-arthritis-drug-idUSKCN2291OD?feedType=RSS&feedName=healthNews
https://www.biopharmadive.com/news/coronavirus-sanofi-kevzara-study-results-imminent/576733/
https://www.fiercepharma.com/pharma/covid-19-drained-2-6-trillion-market-value-from-big-pharma-q1-but-gilead-and-regeneron
https://www.fiercepharma.com/pharma/sanofi-regeneron-pump-brakes-reworked-kevzara-deal-amid-covid-19-trials
https://www.biospace.com/article/sanofi-and-regeneron-launch-second-kevzara-trial-against-covid-19/
https://www.fiercepharma.com/pharma/sanofi-regeneron-launch-kevzara-repurposing-study-for-covid-19-abroad
https://www.prnewswire.com/news-releases/sanofi-and-regeneron-begin-global-kevzara-sarilumab-clinical-trial-program-in-patients-with-severe-covid-19-301024733.html
https://www.prnewswire.com/news-releases/fda-requires-new-health-warnings-for-cigarette-packages-and-advertisements-301025602.html
https://www.prnewswire.com/news-releases/regeneron-announces-important-advances-in-novel-covid-19-antibody-program-301025247.html
https://health.economictimes.indiatimes.com/news/pharma/sanofi-regeneron-begin-testing-arthritis-drug-as-coronavirus-treatment/74673998
https://www.fiercepharma.com/pharma/could-arthritis-med-kevzara-hold-promise-against-novel-coronavirus-sanofi-regeneron-aim-to
https://www.fiercepharma.com/pharma/regeneron-to-lay-off-15-workers-as-it-restructures-sanofi-partnership
https://www.pharmaceutical-technology.com/news/sanofi-regeneron-antibody-alliance/
https://www.fiercepharma.com/pharma/pharma-industry-blasts-trump-admin-move-to-scrap-biologics-exclusivity-trade-deal
http://www.pharmatimes.com/news/gsk_launches_phiii_programme_for_otilimab_in_ra_1293223
https://pharmaphorum.com/news/sanofi-to-continue-with-cost-cutting-as-new-drugs-show-promise/
https://www.fiercepharma.com/pharma/regeneron-continues-new-york-expansion-800m-project-1-500-jobs
https://www.prnewswire.com/news-releases/us-rheumatologists-early-views-on-eli-lillys-olumiant-for-the-treatment-of-rheumatoid-arthritis-show-uphill-battle-while-pfizers-xeljanz-holds-ground-as-the-preferred-jak-inhibitor-300699560.html
Market Place
Share 
